PNC-27
Membrane HDM-2 Targeting & Tumour-Selective Necrosis (Preclinical)
PNC-27 — p53(12–26)–Penetratin Chimeric Anticancer Peptide
Last reviewed: September 2026
PNC-27 is a laboratory-designed peptide that joins a piece of the tumour-suppressor protein p53 to a cell-penetrating tail. Researchers expected it to work inside cells; instead it kills cancer cells from the outside by latching onto a protein (HDM-2) that cancer cells unusually display on their surface and forming holes in the membrane.
In dishes and in mice, it rapidly kills many kinds of cancer cells — pancreatic, breast, colon, melanoma, leukaemia — and leaves normal cells alone because they do not have HDM-2 on their surface.
The mechanism does not depend on p53 status or apoptosis, so tumours resistant to standard drugs are still sensitive in the lab, and cells did not develop resistance in vitro. That is a scientifically interesting profile.
Two decades of promising lab and mouse data, no human trial, no approval. Anyone selling PNC-27 as a cancer therapy is going far beyond the evidence. Research-only.
What is PNC-27?
PNC-27 is a 32-residue chimeric peptide designed at SUNY Downstate in the early 2000s. It fuses residues 12–26 of the tumour-suppressor protein p53 — the segment that binds the p53 regulator MDM2/HDM-2 — to penetratin, a 17-residue cell-penetrating sequence from the Drosophila Antennapedia homeodomain. The design intent was to disrupt the p53–HDM-2 interaction inside cancer cells; what the Pincus laboratory found instead was that PNC-27 kills cancer cells from the outside, by binding HDM-2 that is aberrantly displayed in the plasma membrane of transformed cells and punching pores through it.
Across more than two decades of preclinical work, PNC-27 has induced rapid necrosis of pancreatic, breast, colon, melanoma and leukaemia cell lines, spared untransformed cells that lack membrane HDM-2, and shrunk xenografts in mice. It remains a laboratory compound: no human trial has been registered or published, and it is not an approved drug anywhere.
- PNC-27 is a 32-residue chimera of p53 residues 12–26 and penetratin (≈4,089 Da (average mass, calculated from the 32-residue sequence)), designed at SUNY Downstate.
- Mechanism: binds HDM-2 in cancer-cell plasma membranes, oligomerises into transmembrane pores, causes rapid caspase-independent necrosis; normal cells lacking membrane HDM-2 are spared.
- Evidence: selective killing across solid-tumour and leukaemia cell lines and xenograft regression in mice (Kanovsky 2001; Sarafraz-Yazdi 2010; Sookraj 2020; reviewed 2022).
- No human clinical trial has been registered or published; not an approved drug anywhere.
- Purgo Labs sells PNC-27 as a 10mg vial ($109.99, read 10 Sep 2026) for laboratory research only.
Molecular Composition
PNC-27 is a linear 32-amino-acid peptide: the HDM-2-binding domain of p53 (residues 12–26, PPLSQETFSDLWKLL) joined at its C-terminus to the penetratin sequence (KKWKMRRNQFWVKVQRN), molecular weight approximately 4,032 Da. NMR studies show the p53 segment of PNC-27 adopts the same amphipathic α-helix seen when p53 binds HDM-2, which is why the peptide recognises HDM-2 wherever it is presented. A control peptide, PNC-29, carries an unrelated sequence with the same penetratin tail and is inactive. Supplied as a lyophilized powder for reconstitution.
How Does It Work?
PNC-27 anchors to HDM-2 displayed on the surface of cancer cells and drills pores through their membranes, killing them by necrosis while sparing normal cells that lack membrane HDM-2 — shown in cell lines and mouse xenografts only.
Cancer cells frequently express HDM-2 (the human MDM2 protein) not only in the nucleus but in the plasma membrane; untransformed cells do not. The p53(12–26) segment of PNC-27 binds this membrane HDM-2, anchoring the peptide at the cell surface, while the penetratin segment inserts into the lipid bilayer. Multiple PNC-27 molecules then assemble into transmembrane pores of roughly 1–2 µm, causing rapid loss of membrane integrity, LDH release and necrotic cell death within hours — a mechanism independent of p53 status, caspase activation or apoptosis.
The selectivity argument rests on membrane HDM-2: cells engineered to express HDM-2 at the surface become sensitive, HDM-2 knockdown confers resistance, and normal fibroblasts, hepatocytes and haematopoietic progenitors are spared. Later work reported an additional interaction with mitochondrial membranes in cancer cells, contributing to mitochondrial disruption. Because the mechanism is physical pore formation rather than a signalling cascade, cells do not develop the usual pathway-based resistance in vitro.
Key Research Pathways
Membrane HDM-2 Recognition
The p53(12–26) segment binds HDM-2 aberrantly expressed in cancer-cell plasma membranes; this anchoring step confers tumour selectivity.
Penetratin-Driven Membrane Insertion
The Antennapedia-derived tail inserts into the bilayer; oligomerisation of anchored peptides forms 1–2 µm transmembrane pores.
Necrotic Cell Death
Pore formation causes rapid LDH release and membrane collapse — death is p53-independent and caspase-independent, so p53-mutant tumours remain sensitive.
Mitochondrial Membrane Disruption
Reported secondary interaction with cancer-cell mitochondrial membranes contributes to loss of viability.
Key Findings from the Literature
- PNC-27 adopts the HDM-2-binding conformation of p53 and kills cancer cells by binding HDM-2 in their plasma membranes, forming transmembrane pores; untransformed cells lacking membrane HDM-2 are spared (Sarafraz-Yazdi et al., PNAS 2010; PMID 20080680)
- Peptides from the p53 MDM-2-binding domain, designed from conformational analysis, were selectively cytotoxic to transformed cells — the founding study of the PNC series (Kanovsky et al., PNAS 2001; PMID 11606716)
- PNC-27 induced necrosis in acute myeloid and lymphoblastic leukaemia cells that express membrane HDM-2, but not in normal haematopoietic cells (Sookraj et al., 2010; PMID 20182728)
- PNC-27 causes mitochondrial membrane disruption in addition to plasma-membrane pore formation in cancer cells (Krzesaj et al., Ann Clin Lab Sci 2024; PMID 38802154)
- A 2022 review consolidated two decades of PNC-27 data: selective membranolysis across solid-tumour and leukaemia lines and xenograft regression, with no human trial to date (Biomedicines 2022; PMID 35625682)
Important Research Context
Research References
Peer-reviewed literature supporting the research profile of PNC-27
The following peer-reviewed studies form the primary evidence base for PNC-27's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Kanovsky M, et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proceedings of the National Academy of Sciences. 2001.PMID: 11606716
p53(12–26)-penetratin peptides selectively killed transformed cells — origin of the PNC series.
- 2.
Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences. 2010.PMID: 20080680
PNC-27's p53 segment adopts the HDM-2-bound conformation; the peptide binds membrane HDM-2 and induces pore-mediated necrosis in cancer cells, sparing untransformed cells.
- 3.
Sookraj KA, et al. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology. 2010.PMID: 20182728
PNC-27 killed AML and ALL cells expressing membrane HDM-2 without affecting normal haematopoietic cells.
- 4.
Sarafraz-Yazdi E, et al. PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. International Journal of Molecular Sciences. 2022.PMID: 35625682
Review consolidating two decades of PNC-27 preclinical evidence; no human trial.
PNC-27
Oncology Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
Use code HEALTH for 20% off
Fast FedEx shipping · Discreet packaging
Technical Specifications
| Peptide Class | Chimeric p53(12–26)–penetratin peptide, 32 aa |
| Molecular Weight | ≈4,089 Da (average mass, calculated from the 32-residue sequence) |
| Target | Plasma-membrane HDM-2 (MDM2) on transformed cells |
| Mode of Death | Transmembrane pore formation → necrosis (caspase-independent) |
| Origin | SUNY Downstate (Pincus / Michl laboratories) |
| Available Size | 10mg vial (3 mL) |
| Form | Lyophilized powder |
| Human Trials | None registered or published |
View full legal status guide →
Source PNC-27 at Purgo Labs
≥99% purity · Third-party COA · Use code HEALTH for 20% off
Other Compounds in This Guide
Supporting Research
PNC-27 has consistent preclinical evidence — cell lines, primary tumour cells and mouse xenografts — for tumour-selective necrosis via membrane HDM-2 binding and pore formation. No human data exist.
References
- Sarafraz-Yazdi E, et al.PRECLINICAL — cells / miceProceedings of the National Academy of Sciences. 2010. PubMedMembrane HDM-2-dependent pore formation and selective cancer-cell necrosis.
- Sookraj KA, et al.PRECLINICAL — primary leukaemia cellsCancer Chemotherapy and Pharmacology. 2010. PubMedSelective necrosis of leukaemia cells; normal haematopoietic cells spared.
Research Databases
Ready to Source PNC-27?
Purgo Labs offers PNC-27 with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.